ruxolitinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 4190 941678-49-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ruxolitinib
  • jakafi
  • INCB 018424
  • ruxolitinib phosphate
  • jakavi
a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Although some small studies have suggested possibility of benefit from ruxolitinib in patients with COVID-19, it is not recommended the use of JAK inhibitors other than baricitinib for the treatment of COVID-19.
  • Molecular weight: 306.37
  • Formula: C17H18N6
  • CLOGP: 2.22
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 83.18
  • ALOGS: -3.42
  • ROTB: 4

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 16, 2011 FDA INCYTE CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count decreased 392.83 18.58 297 14992 99727 46571046
Platelet count increased 383.46 18.58 154 15135 14720 46656053
Haemoglobin decreased 356.60 18.58 312 14977 128637 46542136
Splenomegaly 352.67 18.58 129 15160 9559 46661214
Myelofibrosis 244.34 18.58 61 15228 1198 46669575
Blood count abnormal 236.67 18.58 116 15173 17762 46653011
Anaemia 201.33 18.58 325 14964 255454 46415319
Weight increased 178.15 18.58 243 15046 164230 46506543
Product dose omission issue 157.37 18.58 232 15057 168288 46502485
Death 154.52 18.58 339 14950 335209 46335564
Contusion 153.14 18.58 165 15124 87322 46583451
White blood cell count increased 148.60 18.58 120 15169 44099 46626674
Red blood cell count decreased 112.69 18.58 90 15199 32533 46638240
Acute myeloid leukaemia 97.33 18.58 62 15227 15716 46655057
Increased appetite 85.73 18.58 46 15243 8481 46662292
Thrombocytopenia 78.37 18.58 145 15144 126436 46544337
Primary myelofibrosis 75.44 18.58 14 15275 58 46670715
Flatulence 73.75 18.58 67 15222 28811 46641962
Dizziness 64.84 18.58 251 15038 340163 46330610
Fatigue 62.98 18.58 376 14913 608321 46062452
Drug hypersensitivity 55.98 18.58 7 15282 243818 46426955
Night sweats 50.41 18.58 53 15236 27197 46643576
Haematocrit decreased 49.13 18.58 59 15230 34998 46635775
Febrile neutropenia 47.13 18.58 99 15190 94528 46576245
Abdominal distension 41.58 18.58 81 15208 73270 46597503
Bone pain 39.96 18.58 62 15227 46828 46623945
Transfusion 38.36 18.58 33 15256 13198 46657575
Drug ineffective 38.08 18.58 106 15183 677732 45993041
Graft versus host disease in liver 36.40 18.58 11 15278 447 46670326
Graft versus host disease 35.99 18.58 24 15265 6564 46664209
Graft versus host disease in gastrointestinal tract 35.07 18.58 17 15272 2533 46668240
Epistaxis 34.02 18.58 69 15220 64236 46606537
Platelet count abnormal 33.73 18.58 17 15272 2755 46668018
Therapeutic response unexpected 33.67 18.58 33 15256 15583 46655190
Fungal endocarditis 33.07 18.58 9 15280 250 46670523
Muscle spasms 32.19 18.58 101 15188 123012 46547761
White blood cell count decreased 32.08 18.58 95 15194 112136 46558637
Splenectomy 31.94 18.58 10 15279 458 46670315
Eye infection bacterial 29.50 18.58 7 15282 110 46670663
Spleen disorder 28.79 18.58 11 15278 917 46669856
Infective aneurysm 28.40 18.58 9 15280 429 46670344
Gout 28.30 18.58 26 15263 11330 46659443
Product use in unapproved indication 28.29 18.58 79 15210 90194 46580579
Leukaemia 28.23 18.58 16 15273 3279 46667494
Iron overload 27.16 18.58 10 15279 752 46670021
Bronchopulmonary aspergillosis 26.54 18.58 21 15268 7475 46663298
Blast cell count increased 25.84 18.58 8 15281 353 46670420
Toxicity to various agents 25.83 18.58 19 15270 211747 46459026
Haemorrhage 25.67 18.58 56 15233 54813 46615960
Headache 24.75 18.58 252 15037 478100 46192673
Second primary malignancy 24.51 18.58 19 15270 6565 46664208
Cytomegalovirus infection reactivation 23.89 18.58 11 15278 1461 46669312
Pancytopenia 23.35 18.58 71 15218 84987 46585786
Overdose 23.20 18.58 3 15286 101976 46568797
Chronic graft versus host disease 22.72 18.58 13 15276 2712 46668061
JC virus infection 22.62 18.58 11 15278 1651 46669122
Drug interaction 22.55 18.58 20 15269 203074 46467699
Herpes zoster 21.86 18.58 60 15229 67812 46602961
Condition aggravated 21.82 18.58 29 15260 245023 46425750
Adenocarcinoma metastatic 21.67 18.58 5 15284 69 46670704
Blood lactate dehydrogenase increased 21.64 18.58 30 15259 20470 46650303
Asthenia 21.19 18.58 174 15115 310901 46359872
Acute leukaemia 20.03 18.58 9 15280 1129 46669644
Leukocytosis 20.01 18.58 31 15258 23367 46647406
Encopresis 19.75 18.58 5 15284 104 46670669
Encephalitis fungal 19.67 18.58 4 15285 29 46670744
Aspergillus infection 19.59 18.58 17 15272 6873 46663900
Epstein-Barr virus infection reactivation 19.48 18.58 6 15283 260 46670513
Red blood cell count increased 19.03 18.58 11 15278 2339 46668434
Promyelocyte count increased 19.00 18.58 3 15286 3 46670770
Graft versus host disease in skin 18.96 18.58 11 15278 2356 46668417

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myelofibrosis 386.07 16.56 103 17117 1468 29933790
Splenomegaly 385.33 16.56 177 17043 13303 29921955
Platelet count decreased 330.15 16.56 353 16867 105776 29829482
Death 246.64 16.56 594 16626 356689 29578569
Haemoglobin decreased 224.82 16.56 301 16919 113797 29821461
Anaemia 204.89 16.56 400 16820 207592 29727666
Platelet count increased 186.55 16.56 94 17126 8648 29926610
White blood cell count increased 161.51 16.56 153 17067 39520 29895738
Blood count abnormal 153.32 16.56 91 17129 11561 29923697
Acute myeloid leukaemia 141.95 16.56 102 17118 17904 29917354
Product dose omission issue 126.91 16.56 205 17015 91426 29843832
Febrile neutropenia 123.06 16.56 220 17000 106473 29828785
Second primary malignancy 122.99 16.56 64 17156 6292 29928966
Contusion 81.28 16.56 95 17125 31185 29904073
Red blood cell count decreased 80.45 16.56 87 17133 26234 29909024
Fatigue 68.93 16.56 364 16856 320309 29614949
Blast cell count increased 65.03 16.56 24 17196 1025 29934233
Night sweats 64.77 16.56 59 17161 14469 29920789
Iron overload 60.37 16.56 24 17196 1257 29934001
Acute leukaemia 59.52 16.56 23 17197 1116 29934142
Toxicity to various agents 52.87 16.56 18 17202 177165 29758093
Drug interaction 50.37 16.56 26 17194 199542 29735716
Nocardiosis 48.09 16.56 28 17192 3427 29931831
Weight increased 47.24 16.56 121 17099 74792 29860466
Thrombocytopenia 46.97 16.56 179 17041 136865 29798393
Graft versus host disease 46.77 16.56 42 17178 10108 29925150
Epistaxis 45.95 16.56 97 17123 52884 29882374
Completed suicide 45.44 16.56 3 17217 99489 29835769
Graft versus host disease in gastrointestinal tract 43.06 16.56 25 17195 3044 29932214
Transfusion 42.79 16.56 35 17185 7426 29927832
Leukocytosis 42.54 16.56 57 17163 21445 29913813
Flatulence 42.05 16.56 52 17168 18077 29917181
Blast cells present 40.93 16.56 11 17209 161 29935097
Platelet count abnormal 40.69 16.56 22 17198 2335 29932923
Haematocrit decreased 40.10 16.56 67 17153 30632 29904626
Early satiety 39.92 16.56 14 17206 515 29934743
Leukaemia 38.84 16.56 24 17196 3273 29931985
Pneumonia 38.44 16.56 325 16895 333981 29601277
Primary myelofibrosis 38.10 16.56 9 17211 75 29935183
Eye infection fungal 37.96 16.56 12 17208 318 29934940
Graft versus host disease in liver 34.48 16.56 15 17205 987 29934271
Blast cell crisis 32.56 16.56 8 17212 80 29935178
Overdose 32.18 16.56 5 17215 84332 29850926
Squamous cell carcinoma 31.51 16.56 34 17186 10216 29925042
Hypotension 31.05 16.56 42 17178 200523 29734735
Polycythaemia vera 29.64 16.56 9 17211 208 29935050
Thyroid gland abscess 29.05 16.56 7 17213 64 29935194
Necrotising retinitis 28.74 16.56 12 17208 713 29934545
Retinal ischaemia 28.67 16.56 10 17210 362 29934896
Splenectomy 27.72 16.56 10 17210 400 29934858
Adenovirus infection 26.55 16.56 21 17199 4247 29931011
Infectious thyroiditis 26.14 16.56 7 17213 101 29935157
Skin cancer 25.51 16.56 27 17193 7934 29927324
Increased appetite 25.40 16.56 23 17197 5594 29929664
Varicella zoster virus infection 25.19 16.56 13 17207 1255 29934003
Haemorrhage 24.56 16.56 70 17150 46009 29889249
Graft versus host disease in skin 24.37 16.56 18 17202 3289 29931969
Serum ferritin increased 24.07 16.56 22 17198 5415 29929843
Herpes zoster 23.85 16.56 53 17167 29890 29905368
Gout 22.88 16.56 38 17182 17277 29917981
Cardio-respiratory arrest 22.78 16.56 3 17217 57303 29877955
White blood cell count decreased 22.68 16.56 102 17118 83845 29851413
Product use in unapproved indication 22.56 16.56 93 17127 73600 29861658
Spleen disorder 22.22 16.56 11 17209 972 29934286
Haematocrit increased 21.80 16.56 13 17207 1663 29933595
Syncope 21.46 16.56 11 17209 84892 29850366
Therapeutic response unexpected 21.39 16.56 26 17194 8877 29926381
Procedural pneumothorax 21.35 16.56 5 17215 40 29935218
Plasma cell myeloma 20.78 16.56 3 17217 53459 29881799
Splenic infarction 20.77 16.56 13 17207 1812 29933446
Septic embolus 20.73 16.56 11 17209 1124 29934134
Seizure 20.44 16.56 16 17204 98459 29836799
Drug hypersensitivity 20.33 16.56 7 17213 68512 29866746
Cerebral artery embolism 19.99 16.56 10 17210 904 29934354
Myeloproliferative neoplasm 19.76 16.56 8 17212 439 29934819
Cytopenia 19.65 16.56 24 17196 8232 29927026
Scleroderma 19.12 16.56 11 17209 1316 29933942
Graft versus host disease in lung 18.72 16.56 8 17212 504 29934754
Haematoma 18.63 16.56 42 17178 23911 29911347
Tuberculosis 18.45 16.56 23 17197 8054 29927204
Red blood cell count increased 18.36 16.56 11 17209 1418 29933840
Microangiopathy 18.23 16.56 9 17211 791 29934467
Blood product transfusion dependent 18.03 16.56 7 17213 344 29934914
Enterocolitis infectious 17.64 16.56 10 17210 1164 29934094
Basophil count increased 17.63 16.56 7 17213 365 29934893
Acute graft versus host disease in intestine 17.52 16.56 13 17207 2392 29932866
Serum ferritin abnormal 17.26 16.56 6 17214 215 29935043
Chronic myelomonocytic leukaemia 16.82 16.56 8 17212 648 29934610
Bone marrow transplant 16.61 16.56 9 17211 959 29934299

Pharmacologic Action:

SourceCodeDescription
ATC L01EJ01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Janus-associated kinase (JAK) inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:76617 abl inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Myelofibrosis indication 52967002 DOID:4971
Polycythemia vera indication 109992005
Myeloproliferative disorder indication 425333006
Coronavirus infection off-label use 186747009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.44 acidic
pKa2 4.6 Basic
pKa3 2.37 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL Dec. 4, 2021 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INULLDEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL Dec. 4, 2021 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INULLDEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL Dec. 4, 2021 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INULLDEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL Dec. 4, 2021 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INULLDEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL Dec. 4, 2021 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INULLDEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2022 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2022 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2022 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2022 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2022 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 10MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2026 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 15MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2026 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 20MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2026 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 25MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2026 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 5MG BASE JAKAFI INCYTE CORP N202192 Nov. 16, 2011 RX TABLET ORAL May 24, 2026 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tyrosine-protein kinase JAK2 Kinase INHIBITOR Kd 10.44 CHEMBL CHEMBL
Tyrosine-protein kinase JAK1 Kinase INHIBITOR Ki 10.05 CHEMBL CHEMBL
Phosphatidylinositol 4-kinase beta Kinase Kd 5.47 CHEMBL
Serine/threonine-protein kinase DCLK1 Kinase Kd 7.17 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 6.33 CHEMBL
SRSF protein kinase 1 Kinase Kd 5.68 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2 Kinase Kd 5.43 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase Nek3 Kinase Kd 5.96 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 6.33 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit beta Kinase Kd 6.51 CHEMBL
Death-associated protein kinase 2 Kinase Kd 7.01 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 6.82 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase Kd 6.92 CHEMBL
Cyclin-G-associated kinase Kinase Kd 7 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase kinase kinase 15 Kinase Kd 5.96 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 6.28 CHEMBL
JAK2/TYK2 Kinase IC50 6.09 CHEMBL
JAK1/JAK2/TYK2 Kinase IC50 6.53 CHEMBL
JAK1/TYK2 Kinase IC50 6.71 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 5.92 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 6 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 5.66 CHEMBL
Serine/threonine-protein kinase PLK1 Kinase Kd 6.89 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 5.77 CHEMBL
Serine/threonine-protein kinase Nek7 Kinase Kd 5.31 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 5.60 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 5.66 CHEMBL
Serine/threonine-protein kinase OSR1 Kinase Kd 5.57 CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase Kinase Kd 5.72 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 6.14 CHEMBL
Dual specificity protein kinase CLK2 Kinase Kd 6.34 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 6.27 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 5.92 CHEMBL
JAK3/JAK1 Kinase IC50 7.64 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 6.32 CHEMBL
JAK2/JAK1 Kinase IC50 7.51 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.21 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 6.31 CHEMBL
Serine/threonine-protein kinase 17B Kinase Kd 5.46 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase Kd 7 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 6.70 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 6.92 CHEMBL
Serine/threonine-protein kinase MARK2 Kinase Kd 6.18 CHEMBL
Protein kinase C epsilon type Kinase Kd 6.28 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 8.70 CHEMBL
Ribosomal protein S6 kinase alpha-5 Kinase Kd 6.85 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 5.48 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 5.89 CHEMBL
Aurora kinase C Kinase Kd 5.06 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 6 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 5.82 CHEMBL
Rho-associated protein kinase 1 Kinase Kd 7.22 CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1 Kinase Kd 6.41 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 5.20 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 6.44 CHEMBL
Serine/threonine-protein kinase DCLK2 Kinase Kd 6.12 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 7.05 CHEMBL
Serine/threonine-protein kinase PAK 6 Kinase Kd 5.54 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 5.20 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 6.68 CHEMBL
Serine/threonine-protein kinase PAK 7 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 5.21 CHEMBL
Ribosomal protein S6 kinase alpha-4 Kinase Kd 6.47 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 5.77 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 6.70 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 5.74 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Ki 9.30 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 6.54 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 6.92 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G Kinase Kd 5.66 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit beta Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 6.51 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 6.82 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 6.72 CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase Kd 5.24 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 5.59 CHEMBL
Casein kinase II subunit alpha Kinase Kd 5.38 CHEMBL
NT-3 growth factor receptor Kinase Kd 6.48 CHEMBL
Rhodopsin kinase Kinase Kd 6.14 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 7.34 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 5.21 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 7.39 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 5.51 CHEMBL
Serine/threonine-protein kinase PLK2 Kinase Kd 5.82 CHEMBL
Bone morphogenetic protein receptor type-2 Kinase Kd 6.03 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 5.92 CHEMBL
Peripheral plasma membrane protein CASK Kinase Kd 5.82 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 5.51 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 5.32 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 6.23 CHEMBL
Casein kinase I isoform alpha Kinase Kd 5.74 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.38 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 5.48 CHEMBL
Serine/threonine-protein kinase SIK3 Kinase Kd 5.89 CHEMBL
Rho-associated protein kinase 2 Kinase Kd 7.28 CHEMBL
Death-associated protein kinase 1 Kinase Kd 7.14 CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3 Kinase Kd 5.24 CHEMBL
Death-associated protein kinase 3 Kinase Kd 7.05 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 5.80 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 6.59 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase Kd 6.04 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.72 CHEMBL
Myotonin-protein kinase Kinase Kd 5.46 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 6.36 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 6.57 CHEMBL
Serine/threonine-protein kinase PLK3 Kinase Kd 6.15 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 6.44 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.49 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 5.40 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 5.74 CHEMBL
SRSF protein kinase 3 Kinase Kd 5.48 CHEMBL
Serine/threonine-protein kinase VRK2 Kinase Kd 5.40 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 5.82 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.82 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 5.60 CHEMBL
Serine/threonine-protein kinase RIO2 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 6.52 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase Kd 7.05 CHEMBL
cGMP-dependent protein kinase 2 Kinase Kd 6.16 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 5.68 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 5.72 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 5.70 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 5.96 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 5.38 CHEMBL

External reference:

IDSource
4031235 VUID
N0000184017 NUI
D09959 KEGG_DRUG
1092939-17-7 SECONDARY_CAS_RN
4031235 VANDF
C3247913 UMLSCUI
CHEBI:66917 CHEBI
RXT PDB_CHEM_ID
CHEMBL1795071 ChEMBL_ID
CHEMBL1789941 ChEMBL_ID
5688 IUPHAR_LIGAND_ID
C540383 MESH_SUPPLEMENTAL_RECORD_UI
9287 INN_ID
DB08877 DRUGBANK_ID
82S8X8XX8H UNII
25126798 PUBCHEM_CID
1193325 RXNORM
186162 MMSL
28206 MMSL
d07812 MMSL
014040 NDDF
014041 NDDF
702806008 SNOMEDCT_US
703779004 SNOMEDCT_US
734494005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
JAKAFI HUMAN PRESCRIPTION DRUG LABEL 1 50881-005 TABLET 5 mg ORAL NDA 28 sections
JAKAFI HUMAN PRESCRIPTION DRUG LABEL 1 50881-010 TABLET 10 mg ORAL NDA 28 sections
JAKAFI HUMAN PRESCRIPTION DRUG LABEL 1 50881-015 TABLET 15 mg ORAL NDA 28 sections
JAKAFI HUMAN PRESCRIPTION DRUG LABEL 1 50881-020 TABLET 20 mg ORAL NDA 28 sections
JAKAFI HUMAN PRESCRIPTION DRUG LABEL 1 50881-025 TABLET 25 mg ORAL NDA 28 sections